Hjem › Interstitielle lungesykdommer › California › Los Angeles
Kliniske studier for Interstitielle lungesykdommer i Los Angeles, CA
14 studier for Interstitielle lungesykdommer søker deltakere på steder i og rundt Los Angeles (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
RekruttererFase 3
- University of Southern California, Los Angeles
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
RekruttererFase 3
- University of California Los Angeles, Los Angeles
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
RekruttererFase 3
- USA010, Los Angeles
- USA023, Los Angeles
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
RekruttererFase 3
- GSK Investigational Site, Los Angeles
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
RekruttererFase 3
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Los Angeles
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
RekruttererFase 2/3
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Los Angeles
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
RekruttererFase 2
- University of Southern California, Los Angeles
- Cedars Sinai Medical Center, Los Angeles
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
RekruttererFase 3
- David Geffen School of Medicine at UCLA, Los Angeles
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
RekruttererObservasjonsstudie
- Cedars-Sinai Medical Center, Los Angeles
Platform Clinical Study for Conquering Scleroderma
RekruttererFase 2
- Keck School of Medicine at USC Medical Center, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
RekruttererObservasjonsstudie
- University of California - Los Angeles, Los Angeles
- University of Southern California, Los Angeles
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
RekruttererFase 3
- Peter Morton Medical Building, Los Angeles
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
RekruttererFase 2
- Keck School of Medicine of USC, Los Angeles
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
RekruttererFase 2
- aTyr Investigative Site, Los Angeles
Interstitielle lungesykdommer-studier i andre byer
- New York City, NY18 studier
- Philadelphia, PA16 studier
- Charleston, SC13 studier
- Kansas City, KS13 studier
- Durham, NC13 studier
- Chicago, IL12 studier
- Houston, TX12 studier
- Aurora, CO11 studier
- Ann Arbor, MI11 studier
- Salt Lake City, UT9 studier
- Dallas, TX9 studier
- Boston, MA9 studier
Andre studier i Los Angeles
- Ikke-småcellet lungekreft87 studier
- Kreft (alle typer)74 studier
- Brystkreft73 studier
- Prostatakreft61 studier
- Kolorektal kreft59 studier
- Metastatisk kreft57 studier
- Eggstokkreft50 studier
- Lungekreft45 studier
- Plateepitelcancer i hode og hals42 studier
- Pankreaskreft35 studier
- Endometriekreft34 studier
- Melanom34 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.